



Considered

3/20/06
PHR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

UMAÑA, et al.

Appl. No.: 10/633,699

Filed: August 5, 2003

For: Glycosylation Engineering of
Antibodies for Improving Antibody-
Dependent Cellular Cytotoxicity

Confirmation No.: 5489

Art Unit: 1646

Examiner: Riggins, P.

Atty. Docket: 1975.0010004/TJS

Declaration Under 37 C.F.R. § 1.132 of Pablo Umaña, Ph.D.

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned, Pablo Umaña, Ph.D., declares and says as follows:

1. I am an inventor of the above-captioned application, U.S. Patent Application Number 10/633,699, filed August 5, 2003, entitled "Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity."
2. I am currently Chief Scientific Officer and Member of the Board at GlycArt Biotechnology AG in Zurich, Switzerland. I am an expert in the fields of molecular biology and immunology, with particular expertise in the area of antibody engineering. My qualifications as an expert are established by the attached curriculum vitae and the publications listed therein. (Exhibit A)
3. I have read and understood the subject matter of U.S. Pat. Appl. No. 10/633,699.
4. Glycoengineered antibodies produced according to the techniques we described in the above-captioned patent application are characterized by a substantial increase in the proportion of nonfucosylated oligosaccharides in their Fc region and